Viral Hepatitis

You have full text access to this OnlineOpen article

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C†

  1. Karin Lindahl1,‡,*,
  2. Lars Stahle2,
  3. Annette Bruchfeld3,
  4. Robert Schvarcz1,§

Article first published online: 19 JAN 2005

DOI: 10.1002/hep.20563

Issue

Hepatology

Hepatology

Volume 41, Issue 2, pages 275–279, February 2005

Additional Information

How to Cite

Lindahl, K., Stahle, L., Bruchfeld, A. and Schvarcz, R. (2005), High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology, 41: 275–279. doi: 10.1002/hep.20563

Author Information

  1. 1

    Departments of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

  2. 2

    Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

  3. 3

    Renal Medicine, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

  1. ‡

    fax: (46) 8-58581916

  2. §

    Potential conflict of interest: Dr. Schvarcz is a recipient of unrestricted grants from Hoffmann LaRoche.

*I 73, Division of Infectious Diseases, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Huddinge SE-141 86, Stockholm, Sweden

  1. †

    See Editorial on Page 234

Publication History

  1. Issue published online: 19 JAN 2005
  2. Article first published online: 19 JAN 2005
  3. Manuscript Accepted: 21 NOV 2004
  4. Manuscript Received: 13 OCT 2004

Funded by

  • Roche AB, Stockholm, Sweden

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (97K)

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan T, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-355.
  • 4
    Lau JY, Tam RC, Liang TJ, Hang Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. HEPATOLOGY 2002; 35: 1002-1009.
    Direct Link:
  • 5
    Jen J, Laughlin M, Chung C, Heft S, Affrim MB, Gupta SK, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349-361.
  • 6
    Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with chronic hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
  • 7
    Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kg bodyweight predict ribavirin induced anaemia. J Viral Hepatol 2004; 11: 84-87.
    Direct Link:
  • 8
    Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-565.
  • 9
    Larrat S, Stanke-Labescque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47: 124-129.
  • 10
    Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. J Viral Hepatol 1999; 6: 237-242.
    Direct Link:
  • 11
    Svensson J-O, Bruchfeld A, Schvarcz R, Ståhle L. Determination of ribavirin in serum using highly selective solid-phase extraction and high performance liquid chromatography. Ther Drug Monit 2000; 22: 215-218.
  • 12
    Yun Z, Lara C, Johansson B, Lorenzana RI, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996; 49: 155-160.
    Direct Link:
View Full Article (HTML) Get PDF (97K)